<DOC>
	<DOC>NCT02873221</DOC>
	<brief_summary>This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.</brief_summary>
	<brief_title>An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine</brief_title>
	<detailed_description>Usual care is the open-label control arm. Dose of ubrogepant (50 mg or 100 mg) will be double-blind for active treatment arms.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Completed study UBRMD01(NCT02828020) or UBRMD02(NCT02867709). Patients with clinically significant electrocardiogram (ECG), vital sign, physical exam, or laboratory abnormalities Requirement for a medication during the study that is on the list of prohibited medications.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>